Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02025036

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer — CRTCOESC  

Stage III Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:
Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer

Clinical Trial Summary

A three-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer. But in China because of its toxic reaction, most of patients stop the halfway. Because low toxicity, the chemotherapy regimen of capecitabine with or without oxaliplatin are widely used in clinical. The purpose of this study is to confirm the difference of Capecitabine plus with or without oxaliplatin over cisplatin plus 5-fluorouracil with definitive chemoradiotherapy for esophagus squamous cell carcinoma. A total of 249 patients will be accrued from China within 2 years. The primary endpoints are grade 3-5 AEs and overall survival and the secondary endpoints include progression-free survival, response rate, pathologic complete response rate.

Clinical Trial Description

We plan to recruit the patients who were pathologically confirmed with esophageal squamous cell carcinoma from the Oct 2014. The patients will be divided into three groups.Experimental group 1 : single drug Capecitabine and concurrent radiotherapy.Experimental group 2: Capecitabine plus oxaliplatin and concurrent radiotherapy. Control group:cisplatin plus 5-fluorouracil and concurrent radiotherapy. To evaluate the adverse events and the overall survival of the three group. Also observe the patient's progression-free survival, response rate, pathologic complete response rate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02025036
Study type Interventional
Source The First Affiliated Hospital of Henan University of Science and Technology
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 2014
Completion date April 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02628665 - Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Phase 3
Recruiting NCT02603159 - Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Phase 3
Recruiting NCT02607540 - Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Phase 3
Recruiting NCT02604615 - The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy Phase 3
Completed NCT02644408 - Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy Phase 3
Recruiting NCT02812641 - Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC Phase 2
Completed NCT02459457 - A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Phase 3